StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the stock.
Ayala Pharmaceuticals Stock Performance
Shares of ADXS opened at $0.28 on Thursday. The business has a 50-day moving average of $0.35 and a 200 day moving average of $0.57. Ayala Pharmaceuticals has a fifty-two week low of $0.13 and a fifty-two week high of $1.95. The firm has a market cap of $11.81 million, a P/E ratio of -0.03 and a beta of 1.45.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) earnings per share for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Stories
- Five stocks we like better than Ayala Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is the FTSE 100 index?
- MarketBeat Week in Review – 6/24 – 6/28
- Comparing and Trading High PE Ratio Stocks
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
